USPTO Grants Patent for Kadimastem Cell Based Treatment

Kadimastem, an Israeli biotechnology company, announced that it has been granted a patent from the United States Patent and Trademark Office (USPTO) for its technology in the field of cell based treatment for diseases of the nervous system. The United States patent joins additional patents granted in Israel and Europe. The patent is for the innovative method of producing supporting cells in the central nervous system from stem cells, including myelin-producing cells, and it is the foundation for the company's products in the field treatment of neurodegenerative diseases. The technology is the fruit of the research of Professor Michel Revel, the company's chief scientist, at the Weizmann Institute. The owner of the patent is Yeda Research and Development Company Ltd. According to an agreement between Kadimastem and Yeda, the company had been granted an exclusive license for exclusive use of the patent. Kadimastem is developing innovative treatments for a number of severe diseases by transplanting cells and tissues differentiated from human stem cells. The patent expands the intellectual property coverage in the American market as part of the company's strategy in the neurodegenerative diseases field in general and ALS in particular.

Kadimastem is a biotechnology company that specializes in the development of human stem cell-based medical solutions for the treatment of diabetes and neurodegenerative diseases, such as ALS and Multiple Sclerosis.